Stem cell transplant plus CAR-T for high-risk leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of your own stem cell transplant and a personalized CAR-T cell therapy called CD19-CAR-T. It is for adults with high-risk acute B-lymphoblastic leukemia whose cancer is in remission after initial chemotherapy, and who are able to receive both treatments safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with high-risk acute B-lymphoblastic leukemia
- Your leukemia is in complete remission after your first chemotherapy
- Doctors were able to make a special CD19-CAR-T treatment from your own cells
- You are healthy enough to receive your own stem cells back after high-dose treatment
- You do not have major organ problems (like heart, liver, or kidney failure)
- You do not have other active cancers, serious infections, or certain viruses (like HIV, hepatitis B, or hepatitis C)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests a treatment plan for people with acute leukemia that has come back or not responded to treatment. It combines CAR-T therapy with a stem cell transplant from a half-matched donor and special immune cell infusions to help prevent relapse.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
Hear when a new Acute Lymphoblastic Leukemia ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.